Omar Cheema, MD
Interventional Cardiology · Milwaukee, WINPI 1255358743
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Penumbra, Inc. at 41.9% of the total.
Across 131 payments — averaging $89.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$5K
- Pfizer$2K
- Abbott$1K
- Medtronic$798
- Abiomed$662
- Novartis$438
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$2,00017%
- Grants$1551%
- Travel & lodging$3,39829%
- Food & beverage$5,83950%
- Education$3633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 13 | $4,927 |
| Pfizer | 10 | $2,208 |
| Abbott | 12 | $1,123 |
| Medtronic(2 entities) | 7 | $798 |
| Abiomed | 11 | $662 |
| Novartis | 19 | $438 |
| Boston Scientific | 9 | $375 |
| E.r. Squibb & Sons, L.L.C. | 15 | $288 |
| AstraZeneca | 7 | $196 |
| Cvrx, Inc. | 1 | $149 |
| Actelion Pharmaceuticals US, Inc. | 2 | $103 |
| Amgen | 4 | $81 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $78 |
| Heartflow, Inc. | 3 | $57 |
| Johnson & Johnson | 3 | $47 |
| Kestra Medical Technology Services, Inc. | 2 | $39 |
| Philips North America LLC | 1 | $33 |
| Novo Nordisk | 1 | $31 |
| Lexicon Pharmaceuticals, Inc. | 1 | $26 |
| Livanova USA, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Terumo Medical Corporation | 1 | $19 |
| Inari Medical, Inc. | 1 | $19 |
| Cook Medical LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RUBY Coil$2,392
- Indigo System$2,324
- VYNDAQEL$2,000
- Impella$392
- HeartWare HVAD$377
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$283
- SYNERGY$211
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$173
- CoreValve Evolut$168
- Barostim Neo System$149
- HeartMate 3 Left Ventricular Assist Device$138
- HeartMate 3 Left Ventricular Dev$137
- EnSite Precision Cardiac Mapping System$136
- COROFLOW$126
- FARXIGA$107
How this compares
$11,756 in reported general payments places this provider in the 70th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 108 | $117,802 |
| EntrestoSacubitril/Valsartan | 72 | $109,582 |
| JardianceEmpagliflozin | 76 | $105,901 |
| FarxigaDapagliflozin Propanediol | 25 | $23,176 |
| BrilintaTicagrelor | 20 | $17,519 |
| Repatha SureclickEvolocumab | 13 | $11,491 |
| Metoprolol Succinate | 219 | $2,851 |
| Losartan Potassium | 202 | $1,734 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 57 | $1,598 |
| Atorvastatin Calcium | 154 | $1,195 |
| ClopidogrelClopidogrel Bisulfate | 106 | $1,113 |
| Torsemide | 38 | $1,043 |
| Carvedilol | 146 | $1,039 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 37 | $725 |
| Furosemide | 94 | $695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,208 | $117,802108 claims |
| NovartisEntresto | $438 | $109,58272 claims |
| Boehringer IngelheimJardiance | $20 | $105,90176 claims |
| AstraZenecaFarxiga, Brilinta | $196 | $40,69645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Milwaukee
- Michael SalingerMilwaukee$216K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Iyad AzzamMilwaukee$60K
- Montoya TaylorMilwaukee$48K
- Mina IskanderMilwaukee$41K
- Anna LarosaMilwaukee$38K
- Louie KostopoulosMilwaukee$26K
- Daniel JohnsrudMilwaukee$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.